Results showed that differences in tumor weights among the sh-NC + EV, sh-SPOP + EV, and sh-SPOP+sh-LMNB2 + EV groups were significantly reduced with Atezolizumab treatment, indicating that elevated LMNB2 promotes tumor immune evasion (Fig. 6B–D). This evidence concerns the gene SPOP and neoplasm.